--- title: "TRIUMPH-2: Retatrutide Phase 3 Results | Primara Labs" url: https://www.primaralabs.com/research/trials/triumph-2 source: Primara Labs, markdown mirror of the HTML page --- # TRIUMPH-2 In TRIUMPH-2, a phase 3 trial of retatrutide in adults with type 2 diabetes and obesity or overweight (n=1,152), mean body weight fell 12.7% on 4 mg, 19.1% on 9 mg and 20.8% on 12 mg over 80 weeks, against 4.0% on placebo (efficacy estimand; Eli Lilly topline release, 23 July 2026). Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked. Updated 24 September 2026 Retatrutide Explained: Triple Agonist Research (Philippines Guide)1:50·[Transcript and chapters](https://www.primaralabs.com/videos/retatrutide) ## Results Mean percent change in body weight by arm, as each source reports it. Navy bars are the trial arms, grey bars the comparator. Bars from different trials are not a head-to-head comparison: populations, durations and estimands differ. A1C fell 1.4, 1.6 and 1.5 points from a baseline of 7.7% on 4, 9 and 12 mg, against 0.2 on placebo. ## Side effects reported In TRIUMPH-2, discontinuation because of adverse events was 3.8% on 4 mg, 11.6% on 9 mg and 7.7% on 12 mg, against 4.9% on placebo. The most frequently reported adverse events were diarrhoea in 27.4% on 4 mg, 33.5% on 9 mg and 33.6% on 12 mg against 13.2% on placebo, nausea in 13.7% on 4 mg, 20.8% on 9 mg and 28.0% on 12 mg against 8.0% on placebo, constipation in 14.0% on 4 mg, 16.2% on 9 mg and 16.8% on 12 mg against 9.4% on placebo and decreased appetite in 5.8% on 4 mg, 12.3% on 9 mg and 17.1% on 12 mg against 4.5% on placebo. | Event | 4 mg | 9 mg | 12 mg | Placebo | | --- | --- | --- | --- | --- | | Discontinuation for adverse events | 3.8% | 11.6% | 7.7% | 4.9% | | Diarrhoea | 27.4% | 33.5% | 33.6% | 13.2% | | Nausea | 13.7% | 20.8% | 28.0% | 8.0% | | Constipation | 14.0% | 16.2% | 16.8% | 9.4% | | Decreased appetite | 5.8% | 12.3% | 17.1% | 4.5% | | Vomiting | 5.5% | 10.2% | 15.7% | 4.2% | | Dysesthesia | 4.5% | 5.6% | 7.3% | 0.7% | | Urinary tract infection | 3.8% | 6.3% | 8.0% | 6.6% | Design ## Trial design and sources Compound Retatrutide Phase 3 Population Adults with type 2 diabetes and obesity or overweight Participants randomised 1,152 Duration 80 weeks Primary endpoint Percent change in body weight from baseline at 80 weeks Estimand efficacy Read out 23 July 2026 - Eli Lilly topline release, 23 July 2026 [open](https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional) · checked 23 September 2026 - ClinicalTrials.gov NCT05929079 [open](https://clinicaltrials.gov/study/NCT05929079) · checked 23 September 2026 - Registry: NCT05929079 Questions ## TRIUMPH-2, answered ### What did TRIUMPH-2 find? In TRIUMPH-2, a phase 3 trial of retatrutide in adults with type 2 diabetes and obesity or overweight (n=1,152), mean body weight fell 12.7% on 4 mg, 19.1% on 9 mg and 20.8% on 12 mg over 80 weeks, against 4.0% on placebo (efficacy estimand; Eli Lilly topline release, 23 July 2026). ### What side effects were reported in TRIUMPH-2? In TRIUMPH-2, discontinuation because of adverse events was 3.8% on 4 mg, 11.6% on 9 mg and 7.7% on 12 mg, against 4.9% on placebo. The most frequently reported adverse events were diarrhoea in 27.4% on 4 mg, 33.5% on 9 mg and 33.6% on 12 mg against 13.2% on placebo, nausea in 13.7% on 4 mg, 20.8% on 9 mg and 28.0% on 12 mg against 8.0% on placebo, constipation in 14.0% on 4 mg, 16.2% on 9 mg and 16.8% on 12 mg against 9.4% on placebo and decreased appetite in 5.8% on 4 mg, 12.3% on 9 mg and 17.1% on 12 mg against 4.5% on placebo. Related ## More on retatrutide - [TRIUMPH-1](https://www.primaralabs.com/research/trials/triumph-1) - [TRIUMPH-3](https://www.primaralabs.com/research/trials/triumph-3) - [TRIUMPH-4](https://www.primaralabs.com/research/trials/triumph-4) - [Retatrutide phase 2 (Jastreboff)](https://www.primaralabs.com/research/trials/retatrutide-phase-2) - [TRIUMPH-5](https://www.primaralabs.com/research/trials/triumph-5) - [TRIUMPH-6](https://www.primaralabs.com/research/trials/triumph-6) - [TRIUMPH-7](https://www.primaralabs.com/research/trials/triumph-7) - [TRIUMPH-8](https://www.primaralabs.com/research/trials/triumph-8) - [TRIUMPH-9](https://www.primaralabs.com/research/trials/triumph-9) - [TRIUMPH-OUTCOMES](https://www.primaralabs.com/research/trials/triumph-outcomes) - [Evidence Map: Retatrutide](https://www.primaralabs.com/research/evidence#retatrutide) - [Retatrutide 20mg](https://www.primaralabs.com/marketplace/retatrutide) ## More videos Retatrutide vs Tirzepatide vs Semaglutide: Trials Compared (PH)1:55·[Transcript and chapters](https://www.primaralabs.com/videos/reta-vs-tirz-vs-sema)